Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.22 0.35 −0.52%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100

Royalty Pharma PLC (RPRX) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a EV/FCF of 29.5×. Over the past ten years it has ranged from −161× (January 2021) to 214× (December 2020); the current reading is higher than 80% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 7.1× 7.94%
FY2024 6.6× 13.80%
FY2023 5.8× (45.91%)
FY2022 10.7× —
FY2021 −124× —
FY2020 −154× —
FY2019 18.6× 0.00%
FY2018 18.6× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 26.3× 4.32%
Jun 2026 25.3× 3.03%
Mar 2026 24.5× 245.88%
Dec 2025 7.1× 4.71%
25 more quarters

Against its own ten years

Low −161× High 214×
Ten-year median 8.4×
Current reading's percentile 75

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on RPRX